ABG-WTT Global Life Science Capital Partners’s Pulmonx LUNG Stock Holding History

ABG-WTT Global Life Science Capital Partners’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-60,204	Closed	-$405K	–	4
2025 Q1	$405K	Hold	60,204	–	–	1.06%	4
2024 Q4	$409K	Hold	60,204	–	–	0.94%	4
2024 Q3	$499K	Hold	60,204	–	–	2.48%	3
2024 Q2	$382K	Hold	60,204	–	–	1.27%	3
2024 Q1	$558K	Hold	60,204	–	–	1.34%	3
2023 Q4	$768K	Hold	60,204	–	–	1.5%	4
2023 Q3	$622K	Hold	60,204	–	–	2.98%	4
2023 Q2	$789K	Hold	60,204	–	–	14.32%	3
2023 Q1	$673K	Hold	60,204	–	–	10.62%	3
2022 Q4	$508K	Hold	60,204	–	–	8.2%	3
2022 Q3	$1M	Hold	60,204	–	–	6.26%	3
2022 Q2	$886K	Hold	60,204	–	–	3.13%	3
2022 Q1	$1.49M	Hold	60,204	–	–	12.13%	3
2021 Q4	$1.93M	Sell	60,204 -33,627	-36%	-$1.23M	26.2%	2
2021 Q3	$3.38M	Hold	93,831	–	–	22.93%	2
2021 Q2	$4.14M	Sell	93,831 -721,188	-88%	-$31.4M	8%	2
2021 Q1	$37.3M	Hold	815,019	–	–	40.66%	2
2020 Q4	$56.3M	Buy	+815,019	New	+$39.9M	49.03%	2

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's LUNG Position: Q2 2025 in Review

ABG-WTT Global Life Science Capital Partners sold out of Pulmonx (LUNG) in Q2 2025, closing a stake of 60,204 shares — an estimated $405K sold.

ABG-WTT Global Life Science Capital Partners first reported a position in LUNG in Q4 2020 and held it in 18 quarters. The position peaked at $56.3M in Q4 2020. 113 funds tracked by Wall St. Rank hold LUNG as of Q2 2025.

ABG-WTT Global Life Science Capital Partners reported no remaining Pulmonx position as of Q2 2025 after selling out during the quarter.
ABG-WTT Global Life Science Capital Partners sold 60,204 Pulmonx shares in Q2 2025, an estimated $405K.
ABG-WTT Global Life Science Capital Partners first reported a position in Pulmonx in Q4 2020 and held it in 18 quarters.
ABG-WTT Global Life Science Capital Partners's Pulmonx position peaked at $56.3M in Q4 2020.
113 funds tracked by Wall St. Rank held Pulmonx as of Q2 2025.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.